KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
M. HEBBAR md , phd
Department of Medical Oncology, University Hospital, Lille
Search for more papers by this authorP. FOURNIER md
Department of Medical Oncology, University Hospital, Lille
Search for more papers by this authorO. ROMANO md
Department of Medical Oncology, University Hospital, Lille
Search for more papers by this authorM. HEBBAR md , phd
Department of Medical Oncology, University Hospital, Lille
Search for more papers by this authorP. FOURNIER md
Department of Medical Oncology, University Hospital, Lille
Search for more papers by this authorO. ROMANO md
Department of Medical Oncology, University Hospital, Lille
Search for more papers by this authorAbstract
HEBBAR M., FOURNIER P. & ROMANO O. (2010) European Journal of Cancer Care19, 145–166KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
The CRYSTAL study demonstrated an advantage in terms of objective response and progression-free survival for the FOLFIRI–cetuximab combination compared with first-line FOLFIRI for patients with metastatic colorectal cancer. The results of an ancillary biological study with screening for a KRAS gene mutation in 540 patients were reported at the 2008 American Society of Clinical Oncology congress. The analysis confirmed the value of adding cetuximab only in the absence of KRAS mutation. These results led to recommend restriction of the use of cetuximab in Europe to patients with a tumour bearing wild-type KRAS. How should this apparent simplification be integrated into clinical practice? The FOLFIRI–cetuximab combination is certainly a useful supplementary first-line option although its place in relation to other high-dose regimens (high-dose FOLFIRI, FOLFOXIRI or FOLFOX-7), conventional chemotherapy plus bevacizumab, or even a fluoropyrimidine alone in the case of unresectable metastases, has yet to be specified. For subsequent lines, no study has prospectively assessed the value of the chemotherapy–anti-epidermal growth factor receptor combination as a function of KRAS status. Should the absence of objective response constantly observed in retrospective analyses in patients with a tumour presenting a KRAS mutation definitively exclude these patients while stable disease (and potentially a slight gain in survival) may be obtained?
REFERENCES
- Adam R., Delvart V., Pascal G., Valeanu A., Castaing D., Azoulay D., Giacchetti S., Paule B., Kunstlinger F., Ghémard O., Levi F. & Bismuth H. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of Surgery 240, 644–657.
- Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D. & Chang D.D. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26, 1626–1634.
-
Bokemeyer C.,
Bondarenko I.,
Hartmann J.T.,
De Braud F.G.,
Volovat C.,
Nippgen J.,
Stroh C.,
Celik I. &
Koralewski P. (2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience.
ASCO congress. Journal of Clinical Oncology
26 (Suppl.), abstr
4000.
10.1200/jco.2008.26.15_suppl.4000 Google Scholar
- Bouché O., Castaing M., Etienne P.L., Texereau P., Auby D., Bedenne L., Rougier P., Gargot D., Gasmi M. & Ducreux M. (2007) Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. ASCO congress. Journal of Clinical Oncology 25 (Suppl.), abstr 4069.
- Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P. & Saltz L.B. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 23, 1803–1810.
-
Cohn A.L.,
Smith D.A.,
Neubauer M.A.,
Houston G.,
Khandelwal P.,
Wiggans R.G.,
Suzuki S.,
Yassine M.,
Deeter R. &
Sikorski R. (2008) Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI.
ASCO congress. Journal of Clinical Oncology
26 (Suppl.), abstr
4127.
10.1200/jco.2008.26.15_suppl.4127 Google Scholar
-
Cunningham D.,
Humblet Y.,
Siena S.,
Khayat D.,
Bleiberg H.,
Santoro A.,
Bets D.,
Mueser M.,
Harstrick A.,
Verslype C.,
Chau I. &
Van Cutsem E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England Journal of Medicine
1351, 337–345.
10.1056/NEJMoa033025 Google Scholar
- Di Fioré F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., Bastit L., Killian A., Sesboüé R., Tuech J.J., Queuniet A.M., Paillot B., Sabourin J.C., Michot F., Michel P. & Frebourg T. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer 96, 1166–1169.
- Di Fioré F., Van Cutsem E., Laurent-Puig P., Siena S., Frattini M., De Roock W., Lièvre A., Sartore-Bianchi A., Bardelli A. & Tejpar S. (2008) Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. ASCO congress. Journal of Clinical Oncology 26 (Suppl.), abstr 4035.
- Ducreux M., Raoul J.L., Marti P., Merrouche Y., Tigaud J.M., Rebischung C. & Boige V. (2008) High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology 74, 17–24.
- Duffour J., Gourgou S., Desseigne F., Debrigode C., Mineur L., Pinguet F., Poujol S., Chalbos P., Bressole F. & Ychou M. (2007) Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 60, 383–389.
- Hebbar M., Wacrenier A., Desauw C., Romano O., Cattan S., Triboulet J.P. & Pruvot F.R. (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs 17, 855–857.
- Hebbar M., Di Fioré F., Giraud C., Giraud C., Gasnault L., Fournier C., Péreira R., Bouché O., Fournier P., Deligny N., Joly J.P., Maes P., Rad E., Michel P. & Adenis A. (2007) Assessment of easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Oncology 73, 185–191.
- Jonker D.J., O’Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., Tebbutt N.C., Van Hazel G., Wierzbicki R., Langer C. & Moore M.J. (2007) Cetuximab for the treatment of colorectal cancer. The New England Journal of Medicine 357, 2040–2048.
- Karapetis C., Khambata-Ford S., Jonker D., O’Callaghan C., Tu D., Tebbutt N., Simes J., Langer C., Moore M. & Zalcberg J.O. (2008) KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer – results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. 10th World Congress on Gastrointestinal Cancer. Abstr 0.037.
- Koopman M., Antonini N.F., Douma J., Wals J., Honkoop A.H., Erdkamp F.L., De Jong R.S., Rodenburg C.J., Vreugdenhil G., Loosveld O.J., Van Bochove A., Sinnige H.A., Creemers G.J., Tesselaar M.E., Slee P.H., Werter M.J., Mol L., Dalesio O. & Punt C.J. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370, 135–142.
- Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., Mirtsching B., Cohn A.L., Pippas A.W., Azarnia N., Tsuchihashi Z., Mauro D.J. & Rowinsky E.K. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Journal of Clinical Oncology 24, 4914–4921.
- Lièvre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Côté J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F. & Laurent-Puig P. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 66, 3992–3995.
- Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F. & Laurent-Puig P. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology 26, 374–379.
- Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W. & Hicklin D.J. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clinical Cancer Research 8, 994–1003.
-
Rivoire M.,
Thezenas S.,
Rebischung C.,
Viret F.,
Guimbaud R.,
François E.,
Ducreux M.,
Quenet F.,
Desseigne F. &
Ychou M. (2008) Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (METHEP).
ASCO congress. Journal of Clinical Oncology
26 (Suppl.), abstr
4075.
10.1200/jco.2008.26.15_suppl.4075 Google Scholar
- Seymour M.T., Maughan T.S., Ledermann J.A., Topham C., James R., Gwyther S.J., Smith D.B., Shepherd S., Maraveyas A., Ferry D.R., Meade A.M., Thompson L., Griffiths G.O., Parmar M.K. & Stephens R.J. (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370, 143–152.
- Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., Vega-Villegas M.E., Eng C., Steinhauer E.U., Prausova J., Lenz H.J., Borg C., Middleton G., Kröning H., Luppi G., Kisker O., Zubel A., Langer C., Kopit J. & Burris H.A. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26, 2311–2319.
- Tournigand C., André T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C. & De Gramont A. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 22, 229–237.
- Van Cutsem E., Nowacki M., Lang I., Cascinu S., Shchepotin I., Maurel J., Rougier P., Cunningham D., Nippgen J. & Köhne C. (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO congress. Journal of Clinical Oncology 25, (Suppl.), abstr 4000.
-
Van Cutsem E.,
Lang I.,
D’haens G.,
Moiseyenko V.,
Zaluski J.,
Folprecht G.,
Tejpar S.,
Kisker O.,
Stroh C. &
Rougier P. (2008a) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience.
ASCO congress. Journal of Clinical Oncology
26 (Suppl.), abstr
2.
10.1200/jco.2008.26.15_suppl.2 Google Scholar
- Van Cutsem E., Lang I., D’Haens G., Moiseyenko V., Zaluski J., Folprecht G., Tejpar S., Nippgen J., Stroh C. & Rougier P. (2008b) KRAS status and efficacy in the CRYSTAL study: first-line treatment of patients with metastatic colorectal cancer receiving FOLFIRI with or without cetuximab. European Society of Medical Oncology Meeting. Annals of Oncology 19 (Suppl 6), abstr 710.
- Xu Y. & Villalona-Calero M.A. (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of Oncology 13, 1841–1851.
- Ychou M., Raoul J.L., Desseigne F., Borel C., Caroli-Bosc F.X., Jacob J.H., Seitz J.F., Kramar A., Hua A., Lefebvre P., Couteau C. & Merrouche Y. (2002) High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 50, 383–391.